Results 1 to 10 of about 712,184 (317)
Chimeric non-antigen receptors in T cell-based cancer therapy
Journal for ImmunoTherapy of Cancer, 2021 Adoptively transferred T cell-based cancer therapies have shown incredible promise in treatment of various cancers. So far therapeutic strategies using T cells have focused on manipulation of the antigen-recognition machinery itself, such as through ...
Andrew Kent, Eduardo Davila, Jitao Guo
doaj +1 more source
Therapeutic applications of engineered chimeric antigen receptors-T cell for cancer therapy
Beni-Suef University Journal of Basic and Applied Sciences, 2022 Background Findings of new targeted treatments with adequate safety evaluations are essential for better cancer cures and mortality rates. Immunotherapy holds promise for patients with relapsed disease, with the ability to elicit long-term remissions ...
Amina Hussain
doaj +1 more source
Toward high-throughput engineering techniques for improving CAR intracellular signaling domains
Frontiers in Bioengineering and Biotechnology, 2023 Chimeric antigen receptors (CAR) are generated by linking extracellular antigen recognition domains with one or more intracellular signaling domains derived from the T-cell receptor complex or various co-stimulatory receptors.
Savannah E. Butler +7 more
doaj +1 more source
Regulator T Cells: Specific for Antigen and/or Antigen Receptors? [PDF]
Scandinavian Journal of Immunology, 2003 AbstractAdaptive immune responses are regulated by many different molecular and cellular effectors. Regulator T cells are coming to their rights again, and these T cells seem to have ordinary α/β T‐cell receptors (TCRs) and to develop in the thymus. Autoimmune responses are tightly regulated by such regulatory T cells, a phenomenon which is beneficial ...
B, Rubin +3 more
openaire +2 more sources
Predicting Cross-Reactivity and Antigen Specificity of T Cell Receptors
Frontiers in Immunology, 2020 Adaptive immune recognition is mediated by specific interactions between heterodimeric T cell receptors (TCRs) and their cognate peptide-MHC (pMHC) ligands, and the methods to accurately predict TCR:pMHC interaction would have profound clinical ...
Chloe H. Lee +8 more
doaj +1 more source
[Chimeric antigen receptor T cells].
Bulletin du cancer, 2021 Chimeric antigen receptor T-cell (CAR T-cells) therapies which are genetically modified T lymphocyte targeting tumor antigens have modified therapeutic landscape in hematology. Aggressive B cells lymphoma are currently treated in daily practice with anti-CD19 CAR T.
Bories, Pierre, Ysebaert, Loïc
openaire +2 more sources
Coexpression of PD-1, 2B4, CD160 and KLRG1 on exhausted HCV-specific CD8+ T cells is linked to antigen recognition and T cell differentiation. [PDF]
PLoS Pathogens, 2010 Exhausted CD8+ T cell responses during chronic viral infections are defined by a complex expression pattern of inhibitory receptors. However, very little information is currently available about the coexpression patterns of these receptors on human virus-
Bertram Bengsch +7 more
doaj +1 more source
A transfer-learning approach to predict antigen immunogenicity and T-cell receptor specificity
eLife, 2023 Antigen immunogenicity and the specificity of binding of T-cell receptors to antigens are key properties underlying effective immune responses. Here we propose diffRBM, an approach based on transfer learning and Restricted Boltzmann Machines, to build ...
Barbara Bravi +6 more
doaj +1 more source
T-cell antigen receptor genes and T-cell recognition [PDF]
Nature, 1988 The four distinct T-cell antigen receptor polypeptides (alpha, beta, gamma, delta) form two different heterodimers (alpha:beta and gamma:delta) that are very similar to immunoglobulins in primary sequence, gene organization and modes of rearrangement.
M M, Davis, P J, Bjorkman
openaire +2 more sources
Genetic Modification of Cytokine Signaling to Enhance Efficacy of CAR T Cell Therapy in Solid Tumors
Frontiers in Immunology, 2021 Chimeric antigen receptor (CAR) T cell therapy has shown unprecedented success in treating advanced hematological malignancies. Its effectiveness in solid tumors has been limited due to heterogeneous antigen expression, a suppressive tumor ...
Navid Ghahri-Saremi +5 more
doaj +1 more source